Bayer hemophilia drug gets label expansion

|About: Bayer A.G. ADR (BAYRY)|By:, SA News Editor

The FDA approves Bayer's (BAYRY) Kogenate FS antihemophilic factor (recombinant) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

In the 84-patient SPINART study, patients under on-demand therapy experienced an average of 15.2x as many bleeds as those on the prophylactic regimen.